Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
SP2086 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the
efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2
Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control